An observational study in Congenital Heart Defect and Heart Defects, Congenital, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Heart Defects, Congenital by Assiut University — 16 open to participants now, 16 under way, none of them phase 3. Heart Defects, Congenital · Assiut University.
Among the 26 studies in Heart Defects, Congenital by Assiut University, this one has the largest planned enrollment of the 20 observational ones that give a count, is one of 7 that started in 2026, is one of 20 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 24th registered.
991 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.
Browse Heart Defects, Congenital studies →16 of the 26 studies in Heart Defects, Congenital by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 16+
Assiut University
Ages 1 mo–18 yrs
Assiut University
Assiut University
Ages 0 days–28 days
Assiut University · Sites in Egypt
Ages 1 mo–2 yrs
By country, each count listing its studies:
Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 119 across 440 observational studies indexed under Heart Defects, Congenital.
Median enrollment 65 across the 6 interventional studies, 75 across the 20 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,079 studies on the registry; 2,177 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
8 of the studies in Heart Defects, Congenital by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07247604Assiut UniversityCongenital Heart Diseases and Developmental Assessment in Cholestatic Infants Under Two Years | 2026-12-01 |
| NCT07373873Assiut UniversityGrowth in Infants With Congenital Heart Disease at AUCH | 2027-03-01 |
| NCT07520149Assiut UniversityChest X-Rays for Early Detection of Congenital Heart Disease in Newborns | 2027-05 |
| NCT07832851Assiut UniversityFetal Cardiac Anomalies at Anomaly Scan: Detection and Pregnancy Outcomes - Assiut 2026 | 2027-09-20 |
| NCT07820163Assiut UniversityPerinatal Cardiology: Bridging Obstetric and Neonatal Care in CHD | 2027-09-26 |
Add all 8 to your calendar (.ics) → With an account.
Among the 26 studies in Heart Defects, Congenital by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Congenital heart defects are among the most common congenital anomalies and cause significant perinatal morbidity and mortality. Prenatal detection allows counseling, multidisciplinary planning and optimization of delivery. This prospective observational cohort study will screen all pregnant women attending the Fetomaternal Unit, Women's Health Hospital, Assiut University for anomaly scan at 18+0 to 22+6 weeks gestation over 12 months. All cases with suspected or detected fetal cardiac anomalies will be consecutively recruited and followed antenatally until delivery and postnatally when possible. Primary outcome is frequency of fetal cardiac anomalies among screened fetuses. Secondary outcomes include frequency of each type of anomaly, NICU admission, need for neonatal cardiac surgery or intervention, and neonatal death. Data will be analyzed using SPSS with descriptive statistics and chi-square or Fisher exact test and t-test or Mann-Whitney as appropriate. P less than 0.05 is considered significant.
All eligible pregnant women attending the Fetomaternal Unit for second-trimester anomaly scanning will undergo standardized fetal anatomical and cardiac assessment including situs, cardiac position and axis, four-chamber view, outflow tracts, three-vessel view, three-vessel-trachea view when possible, and cardiac rhythm. Cases with suspected cardiac anomalies will undergo detailed documentation and fetal echocardiography when clinically indicated according to routine practice. They will be counseled and followed with assessment of fetal growth, cardiac function, hydrops and progression. Pregnancy outcomes including gestational age at delivery, mode of delivery, birth weight, Apgar scores, NICU admission, neonatal cardiac intervention and survival will be collected. Postnatal echocardiography will be recorded when available to confirm antenatal diagnosis. The study involves no experimental intervention.
Pregnant women attending the Fetomaternal Unit for second-trimester anomaly scanning at Women's Health Hospital, Assiut University.
Inclusion Criteria:-
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women undergoing second-trimester anomaly scanning in whom fetal cardiac anomalies are detected or suspected and will be followed for pregnancy and neonatal outcomes.
Frequency of Fetal Cardiac Anomalies Detected at Anomaly Scan
Proportion of fetuses with cardiac anomalies among all fetuses undergoing anomaly screening at 18+0 to 22+6 weeks. Includes any structural abnormality of heart and great vessels
Time frame: At time of anomaly scan, 18+0 to 22+6 weeks gestation
Frequency of Specific Types of Cardiac Anomalies
Number of each type such as VSD, AVSD, Tetralogy of Fallot, TGA, HLHS among affected fetuses
Time frame: At diagnosis, 18+0 to 22+6 weeks and confirmed by fetal echocardiography
Frequency of NICU Admission
Number of neonates with cardiac anomalies who require NICU admission
Time frame: From birth to discharge, up to 28 days after birth
Frequency of Neonatal Cardiac Surgery
Number of neonates who require cardiac surgery or catheter intervention
Time frame: From birth to 28 days after birth
Frequency of Neonatal Death
Number of neonatal deaths within 28 days among neonates with cardiac anomalies
Time frame: From birth to 28 days after birth
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 12 months is below that.
Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.